Zolmitriptan and Human Aggression: Interaction with Alcohol

Total Page:16

File Type:pdf, Size:1020Kb

Zolmitriptan and Human Aggression: Interaction with Alcohol Psychopharmacology (2010) 210:521–531 DOI 10.1007/s00213-010-1851-6 ORIGINAL INVESTIGATION Zolmitriptan and human aggression: interaction with alcohol Joshua L. Gowin & Alan C. Swann & F. Gerard Moeller & Scott D. Lane Received: 13 October 2009 /Accepted: 25 March 2010 /Published online: 21 April 2010 # Springer-Verlag 2010 Abstract Specifically, compared to placebo, zolmitriptan decreased Rationale The serotonin 1B/D (5-HT1B/D) receptor has the aggressive/monetary ratio at the 0.4- and 0.8-g/kg shown potential as a target for decreasing aggression. The alcohol doses. 5-HT1B/D agonist zolmitriptan's ability to reduce aggressive Conclusions A 5-mg dose of zolmitriptan effectively behavior in humans and its interaction with the well-known reduced alcohol-related aggression in an acute dosing aggression-enhancing drug alcohol were examined. protocol, demonstrating an interaction of 5-HT and alcohol Objectives Our objective was to investigate zolmitriptan's in human aggressive behavior. potential to modify human aggression in a laboratory paradigm across a range of alcohol doses. Alcohol has Keywords Serotonin . 5-HT1B/D receptors . Agonist . been consistently associated with aggression and violence, Human behavior . PSAP thus we hoped to expand current understanding of alcohol's role in aggressive behavior via manipulation of the serotonin (5-HT) system. Introduction Methods Eleven social drinkers, seven male, were recruited to participate in a research study lasting 3–4 weeks. Serotonin (5-HT) has a longstanding relationship with Aggression was measured using the point-subtraction aggression and violence that has been demonstrated across aggression paradigm (PSAP), a laboratory model widely gender and species (Westergaard et al. 1999; Miczek et al. used in human aggression studies. Subjects were adminis- 2002). For example, cerebrospinal fluid (CSF) levels of 5- tered 5-mg zolmitriptan and placebo capsules along with hydroxy-indolacetic acid (5-HIAA), a 5-HT metabolite, alcohol doses of 0.0, 0.4 and 0.8 g/kg in a within-subject, have been negatively correlated with lifetime history of counterbalanced dosing design. Data were analyzed as the aggression in an inpatient population who had demonstrat- ratio of aggressive/monetary-earning responses, to account ed past antisocial behavior (Brown et al. 1979). Although for possible changes in overall motor function due to not all studies have found a negative correlation (Moller et alcohol. al. 1996), a meta-analysis found a significant mean effect Results There was a significant alcohol by zolmitriptan size of −0.45 for increased aggressive behavior as 5-HIAA interaction on the aggressive/monetary response ratio. decreases (Moore et al. 2002). Further, individuals with conduct disorder, a personality disorder typified by extreme aggression, have lower 5-HT profiles than healthy controls Electronic supplementary material The online version of this article (Cappadocia et al. 2009). In consequence, the 5-HT system (doi:10.1007/s00213-010-1851-6) contains supplementary material, has shown potential as a target for the therapeutic treatment which is available to authorized users. : : : of aggression (Siever 2008). J. L. Gowin A. C. Swann F. G. Moeller S. D. Lane (*) One established laboratory assessment for human ag- Department of Psychiatry and Behavioral Sciences, gression, the point-subtraction aggression paradigm The University of Texas Health Science Center Houston, Houston, USA (PSAP), is a free-operant measure of aggressive behavior e-mail: [email protected] that allows subjects to subtract money (represented on a 522 Psychopharmacology (2010) 210:521–531 computer screen), later to be exchanged for real money, to regulate inhibitory control of aggression (New et al. from a (non-existent) confederate in a computer task 2004). In mice, the injection of a 5-HT 1B agonist into the (Cherek 1992). Subjects are provoked throughout the ventral orbitofrontal cortex (VO PFC) caused reductions in session by subtractions from their counter (attributed to species-typical aggressive behavior without significantly the confederate) and can freely choose the aggressive altering non-aggressive behaviors (de Almeida et al. 2006). option throughout the course of the task, but they are never Notably, a 5-HT 1B agonist injected into the VO PFC forced to use it. The primary measure of interest is the reduced aggression in socially provoked male mice, demon- frequency with which the individual uses the aggressive strating the potential external validity of 5-HT 1B anti- response option. Thus, the PSAP indexes the frequency of aggressive effects (Centenaro et al. 2008). Studies of human aggressive behavior. By comparison, another common task, 5-HT1B receptors have been inconclusive, as some reports the Taylor aggression procedure (or TAP), measures the link genetic polymorphisms of the 5-HT1B receptor to intensity of aggressive behavior (McCloskey and Berman comorbid alcoholism and ASPD (Lappalainen et al. 1998), 2003;Tayloretal.1976; Parrott and Giacola 2007). while other reports have found no relationship (Huang et al. Previous studies in subjects with histories of frequent 1999). In alcohol-dependent men, a single-nucleotide poly- aggressive behavior, criminal violence and disorders asso- morphism (SNP) of the 5-HT1B receptor predicted a blunted ciated with aggression (substance abuse, antisocial person- growth-hormone response to sumatriptan, a 5-HT1B agonist, ality and borderline personality disorders) have documented suggesting a relationship between 5-HT1B receptor function the external validity of the PSAP (Cherek et al. 1997, 1999; and the development of alcoholism (Moss et al. 2007). Gerra et al. 2004; Golomb et al. 2007; Moeller et al. 1998). Investigating the role of 5-HT1B agonists in humans remains The PSAP has also established sensitivity to 5-HT important, especially given their pre-clinical anti-aggressive manipulation, as one study demonstrated that acutely indications and the evolutionary diversity of aggressive lowering serotonin levels via tryptophan depletion can behavior and 5-HT receptor sub-types. increase aggressive responding (Moeller et al. 1996). When Zolmitriptan, one of numerous triptans, is indicated for tryptophan depletion accompanied alcohol administration, migraine relief by acting as an agonist at the 5-HT 1B/D the effects on aggression were additive and aggressive receptor, causing intracranial blood vessels to contract and responding increased to higher levels than following reduce pressure (Peterlin and Rapoport 2007). Second- alcohol administration or tryptophan depletion alone generation triptans, such as zolmitriptan, appear more (Dougherty et al. 1999). Aggressive responding on the selective for cerebral blood vessels than peripheral blood PSAP was also decreased following acute administration of vessels, and thus pose less ischemic risk than first the non-specific 5-HT releasing agents D-fenfluramine and generation triptans such as sumatriptan (Silva et al. 2007). D,L-fenfluramine (Cherek and Lane 1999; Cherek and Lane Unlike releasing agents such as D- and D,L-fenfluramine or 2001), and chronic administration of the SSRI paroxetine reuptake inhibitors like paroxetine, zolmitriptan is a direct (Cherek et al. 2002). Notably, paroxetine was also recently agonist. Therefore, it represents a potentially unique found to reduce aggression measured via the Taylor mechanism of action with regard to effects on aggressive aggression procedure (Berman et al. 2009). behavior. Research supporting a general serotonin deficiency is Behavioral research using a mouse model demonstrated robust, but receptor function and local 5-HT levels may that zolmitriptan effectively reduced both alcohol- reveal a more precise mechanism through which 5-HT heightened and species-typical aggressive behavior via its alters aggression as opposed to systemic changes. For actions at the post-synaptic 5-HT 1B/D receptor (de Almeida example, Cherek et al. (1999)demonstratedthatviolent et al. 2001). Although zolmitriptan shows efficacy at parolees showed less response to a biochemical challenge by targeting 5-HT receptors in the brain and potential to the 5-HT receptor type 1A (5-HT1A) agonist buspirone mitigate aggression, to date few studies have examined compared to non-violent parolees, and thus may have lower zolmitriptan's behavioral effects in humans. Indeed, this expression or decreased function of 5-HT1A receptors rather experiment represents, to our knowledge, the first explora- than lower levels of 5-HT in general. Research exploring tion of any of the triptans to potentially modify human serotonin receptor expression and pharmacologic manipula- aggression or impulse control. tions targeting specific receptors has pointed to serotonin The γ-amino butyric acid A (GABA-A) receptor also receptors 1A,B and D as well as 2A, B and C as targets for plays an important role in the modulation of aggression (see modulating aggressive behavior (Miczek et al. 2002). de Almeida et al. 2005 review). Both epidemiological and For over a decade, the 5-HT 1B receptor has received experimental data document a well-established relationship attention as a target for anti-aggressive modulation, partic- between alcohol use, via action at the GABA-A receptor ularly due to its high concentration in the orbitofrontal (Harris et al. 2008) and aggression (Bushman 1997; Taylor et cortex (OFC; Boschert et al. 1994), a brain region proposed al. 1976; Martin and Bryant 2001). Although not all people Psychopharmacology
Recommended publications
  • Antimigraine Agents, Triptans Review 07/21/2008
    Antimigraine Agents, Triptans Review 07/21/2008 Copyright © 2004 - 2008 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended
    [Show full text]
  • Frovatriptan Versus Zolmitriptan for the Acute Treatment of Migraine: a Double-Blind, Randomized, Multicenter, Italian Study
    Neurol Sci (2010) 31 (Suppl 1):S51–S54 DOI 10.1007/s10072-010-0273-x SYMPOSIUM: NEWS IN TREATMENT OF MIGRAINE ATTACK Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study Vincenzo Tullo • Gianni Allais • Michel D. Ferrari • Marcella Curone • Eliana Mea • Stefano Omboni • Chiara Benedetto • Dario Zava • Gennaro Bussone Ó The Author(s) 2010. This article is published with open access at Springerlink.com Abstract The objective of this study is to assess patients’ of PF episodes at 2 h was 26% with F and 31% with Z satisfaction with migraine treatment with frovatriptan (F) (p = NS). PR episodes at 2 h were 57% for F and 58% for or zolmitriptan (Z), by preference questionnaire. 133 sub- Z(p = NS). Rate of recurrence was 21 (F) and 24% jects with a history of migraine with or without aura (IHS (Z; p = NS). Time to recurrence within 48 h was better for criteria) were randomized to F 2.5 mg or Z 2.5 mg. The F especially between 4 and 16 h (p \ 0.05). SPF episodes study had a multicenter, randomized, double-blind, cross- were 18 (F) versus 22% (Z; p = NS). Drug-related adverse over design, with each of the two treatment periods lasting events were significantly (p \ 0.05) less under F (3 vs. 10). no more than 3 months. At the end of the study, patients In conclusion, our study suggests that F has a similar were asked to assign preference to one of the treatments efficacy of Z, with some advantage as regards tolerability (primary endpoint).
    [Show full text]
  • Triptans Step Therapy/Quantity Limit Criteria
    Triptans Step Therapy/Quantity Limit Criteria Program may be implemented with the following options 1) step therapy 2) quantity limits or 3) step therapy with quantity limits For Blue Cross and Blue Shield of Illinois Option 1 (step therapy only) will apply. Brand Generic Dosage Form Amerge® naratriptan tablets Axert® almotriptan tablets Frova® frovatriptan tablets Imitrex® sumatriptan injection*, nasal spray, tablets* Maxalt® rizatriptan tablets Maxalt-MLT® rizatriptan tablets Relpax® eletriptan tablets Treximet™ sumatriptan and naproxen tablets Zomig® zolmitriptan tablets, nasal spray Zomig-ZMT® zolmitriptan tablets * generic available and included as target agent in quantity limit edit FDA APPROVED INDICATIONS1-7 The following information is taken from individual drug prescribing information and is provided here as background information only. Not all FDA-approved indications may be considered medically necessary. All criteria are found in the section “Prior Authorization Criteria for Approval.” Amerge® Tablets1, Axert® Tablets2, Frova® Tablets3,Imitrex® injection4, Imitrex Nasal Spray5, Imitrex Tablets6, Maxalt® Tablets7, Maxalt-MLT® Tablets7, Relpax® Tablets8, Treximet™ Tablets9, Zomig® Tablets10, Zomig-ZMT® Tablets10, and Zomig® Nasal Spray11 Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan), Maxalt (rizatriptan), Maxalt-MLT (rizatriptan orally disintegrating), Relpax (eletriptan), Treximet (sumatriptan/naproxen), Zomig (zolmitriptan), and Zomig-ZMT (zolmitriptan orally disintegrating) tablets, and Imitrex (sumatriptan) and Zomig (zolmitriptan) nasal spray are all indicated for the acute treatment of migraine attacks with or without aura in adults. They are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of all of these products have not been established for cluster headache, which is present in an older, predominantly male population.
    [Show full text]
  • Zomig and Zomig Rapimelt Are Trade Marks of the Astrazeneca Group of Companies
    AUSTRALIAN PRODUCT INFORMATION Zomig® and Zomig Rapimelt® (zolmitriptan) 1 NAME OF THE MEDICINE Zolmitriptan 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Zomig is presented as round, yellow (2.5 mg) or pink (5 mg), biconvex film-coated intagliated (with a ‘Z’ on one side) tablets containing 2.5 mg or 5 mg zolmitriptan. The 2.5 mg tablets are 7.4 mm in diameter and are compressed to a weight of 122 mg. The 5 mg tablets are 8.6 mm in diameter and are compressed to a weight of 244 mg. Zomig Rapimelt is presented as orally dispersible white round uncoated orange flavoured tablets containing 2.5 mg zolmitriptan. The tablets are 6.4 mm in diameter, flat-faced with a bevelled edge and intagliated with ‘Z’ on one side. The tablets are compressed to a weight of 100 mg. Excipient(s) with known effect: lactose monohydrate (Zomig), aspartame (Zomig Rapimelt). For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM • Tablet, film-coated • Tablet, dispersible (oral) 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zomig is indicated for the acute treatment of migraine with or without aura. 4.2 DOSE AND METHOD OF ADMINISTRATION The recommended initial dose of Zomig to treat a migraine attack is 2.5 mg. The Zomig conventional tablet should be swallowed whole with water. The Zomig Rapimelt orally dispersible tablet rapidly dissolves when placed on the tongue and is swallowed with the patient’s saliva. A drink of water is not required when taking the Zomig Rapimelt orally dispersible tablet.
    [Show full text]
  • Zolmitriptan Intranasal Spanlastics for Enhanced Migraine Treatment; Formulation Parameters Optimized Via Quality by Design Approach
    Scientia Pharmaceutica Article Zolmitriptan Intranasal Spanlastics for Enhanced Migraine Treatment; Formulation Parameters Optimized via Quality by Design Approach Asmaa Saleh 1, Maha Khalifa 2 , Seham Shawky 2, Amjaad Bani-Ali 3 and Heba Eassa 2,* 1 Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia; [email protected] 2 Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo 11651, Egypt; [email protected] (M.K.); [email protected] (S.S.) 3 Pharmacy Practice Department, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia; [email protected] * Correspondence: [email protected]; Tel.: +20-114-261-2925 Abstract: Zolmitriptan is a potent second-generation triptan prescribed for migraine attacks. It suffers low bioavailability (40%) after oral administration due to the hepatic first-pass metabolism. Spanlastics are surfactant-based elastic vesicular drug carrier systems. This study aimed to design and optimize intranasal spanlastic formulations as an alternative approach that directly targets brain delivery, enhancing its bioavailability and avoiding the first-pass effect. The quality by design approach was applied to correlate the formulation parameters (Span 60 and Tween 80 concentrations) and critical quality attributes (entrapment efficiency (EE%) and particle size). Spanlastic formulations Citation: Saleh, A.; Khalifa, M.; were designed based on response surface central composite design and prepared via an ethanol injec- Shawky, S.; Bani-Ali, A.; Eassa, H. tion method. Designed formulations were characterized by EE% and particle size measurements to Zolmitriptan Intranasal Spanlastics select the optimized formula (with a combination of small particle size and high EE%).
    [Show full text]
  • RELPAX® (Eletriptan Hydrobromide) Tablets
    RELPAX® (eletriptan hydrobromide) Tablets DESCRIPTION RELPAX® (eletriptan) Tablets contain eletriptan hydrobromide, which is a selective 5­ hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist. Eletriptan is chemically designated as (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H­ indole monohydrobromide, and it has the following chemical structure: CH OO OO 3 N S . HBr N H The empirical formula is C22H26N2O2S . HBr, representing a molecular weight of 463.40. Eletriptan hydrobromide is a white to light pale colored powder that is readily soluble in water. Each RELPAX Tablet for oral administration contains 24.2 or 48.5 mg of eletriptan hydrobromide equivalent to 20 mg or 40 mg of eletriptan, respectively. Each tablet also contains the inactive ingredients microcrystalline cellulose NF, lactose NF, croscarmellose sodium NF, magnesium stearate NF, titanium dioxide USP, hypromellose, triacetin USP and FD&C Yellow No. 6 aluminum lake. CLINICAL PHARMACOLOGY Mechanism of Action: Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. Eletriptan has no significant affinity or pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. Two theories have been proposed to explain the efficacy of 5-HT receptor agonists in migraine. One theory suggests that activation of 5-HT1 receptors located on intracranial blood vessels, including those on the arteriovenous anastomoses, leads to vasoconstriction, which is correlated with the relief of migraine headache.
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT [Name to be completed nationally] 2.5 mg film-coated tablets [Name to be completed nationally] 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2.5 mg Each film-coated tablet contains 2.5 mg zolmitriptan Excipient: Lactose, anhydrous 102.50 mg per tablet 5 mg Each film-coated tablet contains 5.0 mg zolmitriptan Excipient: Lactose, anhydrous 205.00 mg per tablet For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet 2.5 mg Yellow coloured, round, biconvex film-coated tablets debossed with 497 on one side and deep break line on other side (diameter approximately: 7 mm). The tablet can be divided into equal halves. 5 mg Pink coloured, round, biconvex film-coated tablets debossed with 498 on one side and plain on other side (diameter approximately: 8.5 mm). 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Zolmitriptan is indicated for the acute treatment of migraine headache with or without aura. It is not indicated for prophylaxis. 4.2 Posology and method of administration The recommended dose of zolmitriptan to treat a migraine attack is 2.5 mg. It is advisable that [Name to be completed nationally] is taken as early as possible after the onset of migraine headache but it is also effective if taken at a later stage. If symptoms of migraine should recur within 24 hours following an initial response, a second dose may be taken. If a second dose is required, it should not be taken within 2 hours of the initial dose.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Zolmitriptan (Zolmig) COMPLEX CHRONIC DISEASES PROGRAM Medication Handout Date: May 15, 2018
    Zolmitriptan (Zolmig) COMPLEX CHRONIC DISEASES PROGRAM Medication Handout Date: May 15, 2018 Medication: Zolmitriptan (Zomig) 2.5 mg or 5 mg What is Zolmitriptan: Zolmitriptan is a type of medication called “triptans” which is used to treat acute migraine headaches. Migraine symptoms may be caused by swollen blood vessels in the head. Zolmitriptan is thought to reduce the swelling of these blood vessels. This helps to take away the headache and other symptoms of a migraine attack, such as feeling or being sick (nausea or vomiting) and being sensitive to light and sound. Zolmitriptan works only when a migraine attack has started. It will not stop you from getting an attack Expected Benefit: Relief should occur within 1 – 2 hrs Watch for possible side effects: This list of side effects is important for you to be aware of however, it is also important to remember that not all side effects happen to all people. If you have problems with these side effects talk with your doctor or pharmacist Heaviness of the arms and legs Flushing Sensation of pins and needles Tightness in the chest, neck, or throat These side effects can be reduced or avoided with a smaller dose or trying a different triptan (e.g., rizatriptan) If you develop muscle spasms and fever, stop the medication and let the clinic know Stopping the medication: There should be no withdrawal effect when stopping the medication as the medication is not taken regularly. How to use and store this medication: Take this medication with or without food Most effective if taken at
    [Show full text]
  • Anti-Migraine Medications
    Active Ingredient Side-effects PATIENT INFORMATION LEAFLET CVS: Spasm, chest pain, numbness and tingling Ergotamine sensation of fingers CNS: Drowsiness, dizziness GIT: Nausea, vomiting, diarrhoea CNS: Dizziness Endocrine: Hot flushes Zolmitriptan Neuromuscular: Paresthesia CNS: Dizziness GIT: Bad taste Sumatriptan Neuromuscular: Tingling sensation ANTI-MIGRAINE CNS: Drowsiness, dizziness, malaise, fatigue MEDICATIONS Naratriptan GIT: Nausea, vomiting Miscellaneous: Pain or pressure in the throat or neck CNS: Drowsiness GIT: Nausea Eletriptan Neuromuscular: Weakness What PRECAUTIONS should I take? Do not use these agents if you are pregnant, trying to become pregnant, or not using adequate contraception, unless you have discussed this with your physician. Inform your doctor if you are breast-feeding and thinking of taking these medications for your migraine attacks. Inform your doctor or pharmacist if you have been (for the past 2 weeks) or are currently on any other medications such as other anti-migraine medications. These medications may cause drowsiness, impair consciousness and judgement. Do not drive or operate machinery when taking these medications. If headaches recur or only a partial response is achieved following an initial dose, the dose may be repeated. However, following failure of a given attack of migraine to respond to the 1st dose, the patient should consult a doctor before repeating a dose. Patients on prolonged ergotamine therapy may experience rebound headaches when the drug is stopped. How should I STORE the medicine? Store the medicine in a cool, dry place. Protect from moisture, heat and direct sunlight. A member of the NUHS SINGHEALTH / PIL / E79R0 ABOUT your medicine The usual adult dose of Ergotamine is 2 tablets followed by another dose in 30 minutes till the attack is abated or until a total of 6 tablets per day or 10 tablets per week are Active Daily/Weekly Dose Onset *Ergotamine, Zolmitriptan, Sumatriptan, taken.
    [Show full text]
  • New Zealand Data Sheet
    New Zealand Data Sheet 1 CAFERGOT (ERGOTAMINE TARTRATE 1 MG AND CAFFEINE 100 MG TABLET) CAFERGOT ergotamine tartrate 1 mg and caffeine 100 mg tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ergotamine tartrate 1 mg and Caffeine 100 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Cafergot tablets are round, flat with bevelled edge, 9 mm diameter, speckled yellow/white, inscribed with a breakline and XL on one side and plain on the other side. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of acute attacks of migraine with or without aura in adults. 4.2 Dose and method of administration Cafergot should be given at the first signs of a migraine attack. Dose Adults First attack: The first time Cafergot is taken, an initial dose of 2 Cafergot tablets orally, is recommended. If relief is not obtained within half an hour, a further tablet should be administered; this may be repeated at half-hourly intervals, but the maximum daily dose of 6 tablets should not be exceeded. Subsequent attacks: If the pain persists, take 1 tablet every half an hour up to the maximum daily dose of 6 tablets. The maximum weekly dose is 10 tablets. Children under 18 years Not recommended. Maximum dose per attack or per day Adults: 6 mg ergotamine tartrate = 6 tablets. Maximum weekly dose Adults: 10 mg ergotamine tartrate = 10 tablets. Special populations Renal impairment Cafergot is contraindicated in patients with severe renal impairment (see Contraindications). Hepatic impairment Cafergot is contraindicated in patients with severe hepatic impairment (see Contraindications).
    [Show full text]
  • Frovatriptan Vs Zolmitriptan Patient Preference Trial Report Signature
    Synopsis of Clinical Study ReportͲƵĚƌĂdŶƵŵďĞƌ͗ϮϬϬϲͲϬϬϬϴϬϱͲϰϮ This Synopsis of Clinical Study Report is provided for patients and healthcare professionals to demonstrate the transparency efforts of the Menarini Group. This document is not intended to replace the advice of a healthcare professional and can not be considered as a recommendation. Patients must always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labelling information approved for the patient's country or region. Data in this document can not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug. The data are property of the Menarini Group or of its licensor(s). Reproduction of all or part of this report is strictly prohibited without prior written permission from an authorized representative of Menarini. Commercial use of the information is strictly prohibited unless with prior written permission of the Menarini Group and is subject to a license fee. Menarini International Operations Luxembourg Protocol MeIn/06/Fro-pp/001 Frovatriptan 2. Synopsis Name of company: Summary table referring (For National
    [Show full text]